当前位置: 首页 >> 检索结果
7161. Genetically Downregulated Interleukin-6 Signaling Is Associated With a Favorable Cardiometabolic Profile: A Phenome-Wide Association Study.
作者: Marios K Georgakis.;Rainer Malik.;Xue Li.;Dipender Gill.;Michael G Levin.;Ha My T Vy.;Renae Judy.;Marylyn Ritchie.;Shefali S Verma.; .;Girish N Nadkarni.;Scott M Damrauer.;Evropi Theodoratou.;Martin Dichgans.
来源: Circulation. 2021年143卷11期1177-1180页 7164. Posterior Left Atrial Adipose Tissue Attenuation Assessed by Computed Tomography and Recurrence of Atrial Fibrillation After Catheter Ablation.
作者: Mohammed El Mahdiui.;Judit Simon.;Jeff M Smit.;Jurrien H Kuneman.;Alexander R van Rosendael.;Ewout W Steyerberg.;Rob J van der Geest.;Lili Száraz.;Szilvia Herczeg.;Nándor Szegedi.;László Gellér.;Victoria Delgado.;Bela Merkely.;Jeroen J Bax.;Pál Maurovich-Horvat.
来源: Circ Arrhythm Electrophysiol. 2021年14卷4期e009135页
[Figure: see text].
7165. Surgical Explantation of Transcatheter Aortic Valve Bioprostheses: A Statewide Experience.
作者: Alexander A Brescia.;G Michael Deeb.;Stephane Leung Wai Sang.;Daizo Tanaka.;P Michael Grossman.;Devraj Sukul.;Chang He.;Patricia F Theurer.;Melissa Clark.;Francis L Shannon.;Stanley J Chetcuti.;Shinichi Fukuhara.; .
来源: Circ Cardiovasc Interv. 2021年14卷4期e009927页
Despite the rapid adoption of transcatheter aortic valve replacement (TAVR) since its initial approval in 2011, the frequency and outcomes of surgical explantation of TAVR devices (TAVR-explant) is poorly understood.
7166. Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial.
作者: Zachary M Gertz.;Howard C Herrmann.;D Scott Lim.;Saibal Kar.;Samir R Kapadia.;Grant W Reed.;Rishi Puri.;Amar Krishnaswamy.;Bernard J Gersh.;Neil J Weissman.;Federico M Asch.;Paul A Grayburn.;Ioanna Kosmidou.;Björn Redfors.;Zixuan Zhang.;William T Abraham.;JoAnn Lindenfeld.;Gregg W Stone.;Michael J Mack.
来源: Circ Cardiovasc Interv. 2021年14卷4期e010300页
Atrial fibrillation (AF), mitral regurgitation (MR), and left ventricular (LV) ejection fraction have a complex interplay. We evaluated the role of AF in patients with heart failure and moderate-to-severe or severe secondary MR enrolled in the randomized COAPT trial (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation) and its impact on mechanisms and outcomes with the MitraClip.
7168. Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria.
作者: Elias J Dayoub.;Ashwin S Nathan.;Sameed Ahmed M Khatana.;Rishi K Wadhera.;Daniel M Kolansky.;Robert W Yeh.;Jay Giri.;Peter W Groeneveld.
来源: Circ Cardiovasc Qual Outcomes. 2021年14卷4期e006887页
In 2009, the American College of Cardiology and American Heart Association published Appropriate Use Criteria for Coronary Revascularization (AUC) to aid patient selection for percutaneous coronary intervention (PCI). The subsequent decline in inappropriate PCIs was interpreted as a success of AUC. However, there are concerns clinicians reclassify nonacute PCIs to acute indications to fulfill AUC.
7169. S-Nitrosylation of Histone Deacetylase 2 by Neuronal Nitric Oxide Synthase as a Mechanism of Diastolic Dysfunction.
作者: Somy Yoon.;Mira Kim.;Hangyeol Lee.;Gaeun Kang.;Kenneth Bedi.;Kenneth B Margulies.;Rajan Jain.;Kwang-Il Nam.;Hyun Kook.;Gwang Hyeon Eom.
来源: Circulation. 2021年143卷19期1912-1925页
Although the clinical importance of heart failure with preserved ejection fraction has been extensively explored, most therapeutic regimens, including nitric oxide (NO) donors, lack therapeutic benefit. Although the clinical characteristics of heart failure with preserved ejection fraction are somewhat heterogeneous, diastolic dysfunction (DD) is one of the most important features. Here we report that neuronal NO synthase (nNOS) induces DD by S-nitrosylation of HDAC2 (histone deacetylase 2).
7170. Extracellular Tuning of Mitochondrial Respiration Leads to Aortic Aneurysm.
作者: Jorge Oller.;Enrique Gabandé-Rodríguez.;María Jesús Ruiz-Rodríguez.;Gabriela Desdín-Micó.;Juan Francisco Aranda.;Raquel Rodrigues-Diez.;Constanza Ballesteros-Martínez.;Eva María Blanco.;Raquel Roldan-Montero.;Pedro Acuña.;Alberto Forteza Gil.;Carlos E Martín-López.;J Francisco Nistal.;Christian L Lino Cardenas.;Mark Evan Lindsay.;José Luís Martín-Ventura.;Ana M Briones.;Juan Miguel Redondo.;María Mittelbrunn.
来源: Circulation. 2021年143卷21期2091-2109页
Marfan syndrome (MFS) is an autosomal dominant disorder of the connective tissue caused by mutations in the FBN1 (fibrillin-1) gene encoding a large glycoprotein in the extracellular matrix called fibrillin-1. The major complication of this connective disorder is the risk to develop thoracic aortic aneurysm. To date, no effective pharmacologic therapies have been identified for the management of thoracic aortic disease and the only options capable of preventing aneurysm rupture are endovascular repair or open surgery. Here, we have studied the role of mitochondrial dysfunction in the progression of thoracic aortic aneurysm and mitochondrial boosting strategies as a potential treatment to managing aortic aneurysms.
7171. Obesity and Outcomes Following Cardiogenic Shock Requiring Acute Mechanical Circulatory Support.
作者: Jayakumar Sreenivasan.;Muhammad Shahzeb Khan.;Parija Sharedalal.;Urvashi Hooda.;Marat Fudim.;Ryan T Demmer.;Melana Yuzefpolskaya.;Hasan Ahmad.;Sadiya S Khan.;Gregg M Lanier.;Paolo C Colombo.;Jonathan D Rich.
来源: Circ Heart Fail. 2021年14卷3期e007937页
The association of obesity on outcomes in patients with cardiogenic shock requiring acute mechanical circulatory support has not been thoroughly investigated.
7172. Cardiac and Noncardiac Disease Burden and Treatment Effect of Sacubitril/Valsartan: Insights From a Combined PARAGON-HF and PARADIGM-HF Analysis.
作者: Luis E Rohde.;Brian L Claggett.;Emil Wolsk.;Milton Packer.;Michael Zile.;Karl Swedberg.;Jean Rouleau.;Marc A Pfeffer.;Akshay S Desai.;Lars H Lund.;Lars Kober.;Inder Anand.;Bela Merkely.;Michele Senni.;Victor Shi.;Adel Rizkala.;Martin Lefkowitz.;John J V McMurray.;Scott D Solomon.
来源: Circ Heart Fail. 2021年14卷3期e008052页
The net clinical benefit of cardiac disease-modifying drugs might be influenced by the interaction of different domains of disease burden. We assessed the relative contribution of cardiac, comorbid, and demographic factors in heart failure (HF) and how their interplay might influence HF prognosis and efficacy of sacubitril/valsartan across the spectrum of left ventricular ejection fraction.
7176. Renal Sympathetic Denervation in Patients With Heart Failure With Preserved Ejection Fraction.
作者: Karl-Patrik Kresoja.;Karl-Philipp Rommel.;Karl Fengler.;Maximilian von Roeder.;Christian Besler.;Christian Lücke.;Matthias Gutberlet.;Steffen Desch.;Holger Thiele.;Michael Böhm.;Philipp Lurz.
来源: Circ Heart Fail. 2021年14卷3期e007421页
Arterial hypertension is the most common comorbidity in patients with heart failure with preserved ejection fraction (HFpEF) and mediates adverse hemodynamics through related aortic stiffness and increased pulsatile load. We aimed to investigate the clinical and hemodynamic implications of renal sympathetic denervation (RDN) in patients with HFpEF and uncontrolled arterial hypertension.
7177. Response by Viray et al to Letter Regarding Article, "Role of Pulmonary Artery Wedge Pressure Saturation During Right Heart Catheterization: A Prospective Study".
作者: Michael C Viray.;Eric L Bonno.;Brian A Houston.;Ryan J Tedford.
来源: Circ Heart Fail. 2021年14卷3期e008304页 |